proxyvotesnow.com

Home › Companies › Capricor Therapeutics, Inc. › 2025-2026

Capricor Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Capricor Therapeutics, Inc.’s Form 8-K, filed 2026-06-08 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 14Reported items
  • 195Asset managers
  • 2,089Fund votes
  • 2026-06-04Meeting date

Proxy season: 2024-2025 2025-2026

Explore Capricor Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Capricor Therapeutics, Inc.

These tallies are Capricor Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-08 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Capricor Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-04
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Frank Litvack, M.D. 21,114,485---- 9,678,90713,030,489 Majority: yes
Elect Director: Linda Marbán, Ph.D. 25,482,880---- 5,310,51213,030,489 Majority: yes
Elect Director: David B. Musket 24,952,805---- 5,840,58713,030,489 Majority: yes
Elect Director: George W. Dunbar, Jr. 24,998,101---- 5,795,29113,030,489 Majority: yes
Elect Director: Karimah Es Sabar 24,428,575---- 6,364,81713,030,489 Majority: yes
Elect Director: Paul Auwaerter, M.D. 25,110,352---- 5,683,04013,030,489 Majority: yes
Elect Director: Philip Gotwals, Ph.D. 25,480,357---- 5,313,03513,030,489 Majority: yes
Elect Director: Michael Kelliher 25,378,932---- 5,414,46013,030,489 Majority: yes
Proposal 2: The ratification of the appointment by the Audit Committee of the Company's Board of Directors of Rose, Snyder & Jacobs LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2026; 43,057,620562,751203,510 ---- Majority: yes
Proposal 3: To approve, by non-binding advisory vote, the resolution approving named executive officer compensation; 24,336,4346,244,316212,642 --13,030,489 Majority: yes
Proposal 5: To approve an amendment to the Certificate of Incorporation regarding officer exculpation. 23,472,2076,433,198887,987 --13,030,489 Majority: yes

Source: Capricor Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-08 — read the filing on EDGAR.

How asset managers voted at the Capricor Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 195 asset managers that disclosed a Capricor Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Capricor Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. APPROVAL OF NAMED EXECUTIVE OFFICER COMPENSATION, ON A NON-BINDING ADVISORY BASIS

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 9 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%AGAINST 20%
FOR: 24,336,434AGAINST: 6,244,316

Capricor Therapeutics, Inc.’s own tally for this item (“Proposal 3: To approve, by non-binding advisory vote, the resolution approving named executive officer compensation;”): 24,336,434 for, 6,244,316 against, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 57,664,673 outstanding shares: 42% for, 11% against (53.0% of the company cast a for/against vote).

The 194 asset managers below cast 97% of the shares they voted on this item FOR (19,888,365 for, 593,131 against).

FOR 97%
FOR: 19,888,365 (97.1%)AGAINST: 593,131 (2.9%)ABSTAIN: 3,098 (0.0%)NOT VOTED: 6 (0.0%)
Largest asset managers voting on “APPROVAL OF NAMED EXECUTIVE OFFICER COMPENSATION, ON A NON-BINDING ADVISORY BASIS” at Capricor Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,545,30313 00For
BlackRock2,298,0684,005 00For
TANG CAPITAL MANAGEMENT LLC2,146,0340 00For
State Street1,885,91510,500 00For
MONTANOVA CAPITAL, LLC1,760,4050 00For
Fidelity1,609,1710 00For
RA CAPITAL MANAGEMENT, L.P.1,507,8440 00For
Palo Alto Investors LP1,280,4390 00For
GEODE CAPITAL MANAGEMENT, LLC839,9410 00For
J. Goldman & Co LP460,0220 00For
DG Capital Management, LLC379,9540 00For
Northern Trust336,1976,999 00For
Invesco0321,755 00Against
Boxer Capital Management, LLC307,0600 00For
Charles Schwab252,0110 00For
RTW INVESTMENTS, LP250,0000 00For
Nuveen223,5520 00For
TIAA212,7600 00For
MOODY ALDRICH PARTNERS LLC143,7160 00For
Ally Bridge Group (NY) LLC106,5630 00For
Wellington74,7840 00For
QUANTITATIVE MASTER SERIES LLC70,8210 00For
Pier Capital, LLC69,6830 00For
Goldman Sachs68,9250 00For
MELLON INVESTMENTS Corp68,4910 00For

Showing the 25 largest of 194 asset managers. See all 194 in the interactive database.

2. APPROVAL OF FREQUENCY OF FUTURE NON-BINDING ADVISORY VOTES ON NAMED EXECUTIVE OFFICER COMPENSATION, ON A NON-BINDING ADVISORY BASIS

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

99.9% fund support · no official result

ONE YEAR 66%1 YEAR 33%

The 185 asset managers below cast 99.9% of the shares they voted on this item FOR (229,672 for, 212 against).

FOR: 229,672 (1.3%)AGAINST: 212 (0.0%)ABSTAIN: 3,026 (0.0%)ONE YEAR: 12,038,972 (65.7%)1 YEAR: 6,058,822 (33.0%)3 YEARS: 1,300 (0.0%)1-YEAR: 356 (0.0%)1.0: 54 (0.0%)1YEAR: 1 (0.0%)2.0: 1 (0.0%)
Largest asset managers voting on “APPROVAL OF FREQUENCY OF FUTURE NON-BINDING ADVISORY VOTES ON NAMED EXECUTIVE OFFICER COMPENSATION, ON A NON-B” at Capricor Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard00 00One Year
BlackRock00 001 Year
State Street00 00One Year
MONTANOVA CAPITAL, LLC00 00One Year
Fidelity00 00One Year
RA CAPITAL MANAGEMENT, L.P.00 00One Year
Palo Alto Investors LP00 001 Year
GEODE CAPITAL MANAGEMENT, LLC00 00One Year
J. Goldman & Co LP00 001 Year
DG Capital Management, LLC00 001 Year
Northern Trust00 001 Year
Invesco00 00One Year
Boxer Capital Management, LLC00 001 Year
Charles Schwab00 001 Year
RTW INVESTMENTS, LP00 00One Year
Nuveen00 00One Year
TIAA00 00One Year
MOODY ALDRICH PARTNERS LLC00 001 Year
Ally Bridge Group (NY) LLC106,5630 00For
Wellington00 001 Year
QUANTITATIVE MASTER SERIES LLC00 001 Year
Pier Capital, LLC00 001 Year
Goldman Sachs00 00One Year
MELLON INVESTMENTS Corp00 00One Year
UBS00 00One Year

Showing the 25 largest of 185 asset managers. See all 185 in the interactive database.

3. ELECTION OF DIRECTORS: Frank Litvack

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

69% Majority: yes · of votes cast

FOR 69%WITHHELD 31%
FOR: 21,114,485WITHHELD: 9,678,907

Capricor Therapeutics, Inc.’s own tally for this item (“Elect Director: Frank Litvack, M.D.”): 21,114,485 for, 9,678,907 withheld, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 57,664,673 outstanding shares: 37% for, 17% withheld (53.4% of the company cast a for/withheld vote).

The 47 asset managers below cast 100% of the shares they voted on this item FOR (4,267,987 for, 0 against).

FOR 68%ABSTAIN 32%
FOR: 4,267,987 (67.9%)ABSTAIN: 2,019,804 (32.1%)
Largest asset managers voting on “ELECTION OF DIRECTORS: Frank Litvack” at Capricor Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,376,3770 4,9130For
Fidelity681,1970 461,9090For
State Street1,043,0900 2,8920For
BlackRock00 785,5530Abstain
TIAA00 212,7600Abstain
Invesco00 154,1850Abstain
Charles Schwab00 125,9880Abstain
QUANTITATIVE MASTER SERIES LLC00 70,8210Abstain
Lincoln Financial37,6490 00For
Equitable27,0900 9,8080For
Northern Trust32,8660 00For
AIG/SunAmerica00 22,2320Abstain
Global X00 20,2970Abstain
RBB FUND, INC.19,3880 00For
JPMorgan16,4140 00For
Brighthouse00 15,5600Abstain
Pacific Life00 14,6260Abstain
Voya00 14,2880Abstain
Dunham Funds12,6240 00For
Putnam00 12,3400Abstain
John Hancock00 11,4540Abstain
MASTER INVESTMENT PORTFOLIO00 11,3100Abstain
Goldman Sachs10,4470 00For
MFS00 8,7550Abstain
Bridge Builder Trust00 8,3000Abstain

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

4. ELECTION OF DIRECTORS: David Musket

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD 19%
FOR: 24,952,805WITHHELD: 5,840,587

Capricor Therapeutics, Inc.’s own tally for this item (“Elect Director: David B. Musket”): 24,952,805 for, 5,840,587 withheld, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 57,664,673 outstanding shares: 43% for, 10% withheld (53.4% of the company cast a for/withheld vote).

The 47 asset managers below cast 100% of the shares they voted on this item FOR (6,266,100 for, 0 against).

FOR 99.6%
FOR: 6,266,100 (99.7%)ABSTAIN: 21,691 (0.3%)
Largest asset managers voting on “ELECTION OF DIRECTORS: David Musket” at Capricor Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,376,3850 4,9050For
Fidelity1,143,1060 00For
State Street1,044,5620 1,4200For
BlackRock785,5530 00For
TIAA212,7600 00For
Invesco154,1850 00For
Charles Schwab125,9880 00For
QUANTITATIVE MASTER SERIES LLC70,8210 00For
Lincoln Financial37,6490 00For
Equitable36,8980 00For
Northern Trust32,8660 00For
AIG/SunAmerica22,2320 00For
Global X20,2970 00For
RBB FUND, INC.19,3880 00For
JPMorgan16,4140 00For
Brighthouse12,5340 3,0260For
Pacific Life14,6260 00For
Voya14,2880 00For
Dunham Funds12,6240 00For
Putnam00 12,3400Abstain
John Hancock11,4540 00For
MASTER INVESTMENT PORTFOLIO11,3100 00For
Goldman Sachs10,4470 00For
MFS8,7550 00For
Bridge Builder Trust8,3000 00For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

5. ELECTION OF DIRECTORS: George Dunbar

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD 19%
FOR: 24,998,101WITHHELD: 5,795,291

Capricor Therapeutics, Inc.’s own tally for this item (“Elect Director: George W. Dunbar, Jr.”): 24,998,101 for, 5,795,291 withheld, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 57,664,673 outstanding shares: 43% for, 10% withheld (53.4% of the company cast a for/withheld vote).

The 47 asset managers below cast 100% of the shares they voted on this item FOR (6,267,675 for, 0 against).

FOR 99.6%
FOR: 6,267,675 (99.7%)ABSTAIN: 20,117 (0.3%)
Largest asset managers voting on “ELECTION OF DIRECTORS: George Dunbar” at Capricor Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,377,9590 3,3300For
Fidelity1,143,1060 00For
State Street1,044,5620 1,4200For
BlackRock785,5530 00For
TIAA212,7600 00For
Invesco154,1850 00For
Charles Schwab125,9880 00For
QUANTITATIVE MASTER SERIES LLC70,8210 00For
Lincoln Financial37,6490 00For
Equitable36,8980 00For
Northern Trust32,8660 00For
AIG/SunAmerica22,2320 00For
Global X20,2970 00For
RBB FUND, INC.19,3880 00For
JPMorgan16,4140 00For
Brighthouse12,5340 3,0260For
Pacific Life14,6260 00For
Voya14,2880 00For
Dunham Funds12,6240 00For
Putnam00 12,3400Abstain
John Hancock11,4540 00For
MASTER INVESTMENT PORTFOLIO11,3100 00For
Goldman Sachs10,4470 00For
MFS8,7550 00For
Bridge Builder Trust8,3000 00For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

6. ELECTION OF DIRECTORS: Karimah Es Sabar

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%WITHHELD 21%
FOR: 24,428,575WITHHELD: 6,364,817

Capricor Therapeutics, Inc.’s own tally for this item (“Elect Director: Karimah Es Sabar”): 24,428,575 for, 6,364,817 withheld, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 57,664,673 outstanding shares: 42% for, 11% withheld (53.4% of the company cast a for/withheld vote).

The 47 asset managers below cast 100% of the shares they voted on this item FOR (6,081,717 for, 0 against).

FOR 97%
FOR: 6,081,717 (96.7%)ABSTAIN: 206,074 (3.3%)
Largest asset managers voting on “ELECTION OF DIRECTORS: Karimah Es Sabar” at Capricor Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,379,7020 1,5870For
Fidelity1,143,1060 00For
State Street1,045,9820 00For
BlackRock785,5530 00For
TIAA212,7600 00For
Invesco00 154,1850Abstain
Charles Schwab125,9880 00For
QUANTITATIVE MASTER SERIES LLC70,8210 00For
Lincoln Financial37,6490 00For
Equitable36,8980 00For
Northern Trust32,8660 00For
AIG/SunAmerica22,2320 00For
Global X00 20,2970Abstain
RBB FUND, INC.19,3880 00For
JPMorgan16,4140 00For
Brighthouse12,5340 3,0260For
Pacific Life14,6260 00For
Voya14,2880 00For
Dunham Funds12,6240 00For
Putnam00 12,3400Abstain
John Hancock11,4540 00For
MASTER INVESTMENT PORTFOLIO11,3100 00For
Goldman Sachs10,4470 00For
MFS8,7550 00For
Bridge Builder Trust8,3000 00For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

7. ELECTION OF DIRECTORS: Paul Auwaerter

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%WITHHELD 18%
FOR: 25,110,352WITHHELD: 5,683,040

Capricor Therapeutics, Inc.’s own tally for this item (“Elect Director: Paul Auwaerter, M.D.”): 25,110,352 for, 5,683,040 withheld, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 57,664,673 outstanding shares: 44% for, 10% withheld (53.4% of the company cast a for/withheld vote).

The 47 asset managers below cast 100% of the shares they voted on this item FOR (6,268,214 for, 0 against).

FOR 99.6%
FOR: 6,268,214 (99.7%)ABSTAIN: 19,577 (0.3%)
Largest asset managers voting on “ELECTION OF DIRECTORS: Paul Auwaerter” at Capricor Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,381,2770 120For
Fidelity1,143,1060 00For
State Street1,045,9820 00For
BlackRock785,5530 00For
TIAA212,7600 00For
Invesco154,1850 00For
Charles Schwab125,9880 00For
QUANTITATIVE MASTER SERIES LLC70,8210 00For
Lincoln Financial37,6490 00For
Equitable36,8980 00For
Northern Trust32,8660 00For
AIG/SunAmerica22,2320 00For
Global X20,2970 00For
RBB FUND, INC.19,3880 00For
JPMorgan16,4140 00For
Brighthouse12,5340 3,0260For
Pacific Life14,6260 00For
Voya14,2880 00For
Dunham Funds12,6240 00For
Putnam00 12,3400Abstain
John Hancock11,4540 00For
MASTER INVESTMENT PORTFOLIO11,3100 00For
Goldman Sachs10,4470 00For
MFS8,7550 00For
Bridge Builder Trust8,3000 00For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

8. ELECTION OF DIRECTORS: Philip Gotwals

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%WITHHELD 17%
FOR: 25,480,357WITHHELD: 5,313,035

Capricor Therapeutics, Inc.’s own tally for this item (“Elect Director: Philip Gotwals, Ph.D.”): 25,480,357 for, 5,313,035 withheld, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 57,664,673 outstanding shares: 44% for, 9% withheld (53.4% of the company cast a for/withheld vote).

The 47 asset managers below cast 100% of the shares they voted on this item FOR (6,272,414 for, 0 against).

FOR 99.7%
FOR: 6,272,414 (99.8%)ABSTAIN: 15,377 (0.2%)
Largest asset managers voting on “ELECTION OF DIRECTORS: Philip Gotwals” at Capricor Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,381,2780 110For
Fidelity1,143,1060 00For
State Street1,045,9820 00For
BlackRock785,5530 00For
TIAA212,7600 00For
Invesco154,1850 00For
Charles Schwab125,9880 00For
QUANTITATIVE MASTER SERIES LLC70,8210 00For
Lincoln Financial37,6490 00For
Equitable36,8980 00For
Northern Trust32,8660 00For
AIG/SunAmerica22,2320 00For
Global X20,2970 00For
RBB FUND, INC.19,3880 00For
JPMorgan16,4140 00For
Brighthouse12,5340 3,0260For
Pacific Life14,6260 00For
Voya14,2880 00For
Dunham Funds12,6240 00For
Putnam00 12,3400Abstain
John Hancock11,4540 00For
MASTER INVESTMENT PORTFOLIO11,3100 00For
Goldman Sachs10,4470 00For
MFS8,7550 00For
Bridge Builder Trust8,3000 00For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

9. ELECTION OF DIRECTORS: Michael Kelliher

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%WITHHELD 18%
FOR: 25,378,932WITHHELD: 5,414,460

Capricor Therapeutics, Inc.’s own tally for this item (“Elect Director: Michael Kelliher”): 25,378,932 for, 5,414,460 withheld, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 57,664,673 outstanding shares: 44% for, 9% withheld (53.4% of the company cast a for/withheld vote).

The 47 asset managers below cast 100% of the shares they voted on this item FOR (6,272,414 for, 0 against).

FOR 99.7%
FOR: 6,272,414 (99.8%)ABSTAIN: 15,377 (0.2%)
Largest asset managers voting on “ELECTION OF DIRECTORS: Michael Kelliher” at Capricor Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,381,2780 110For
Fidelity1,143,1060 00For
State Street1,045,9820 00For
BlackRock785,5530 00For
TIAA212,7600 00For
Invesco154,1850 00For
Charles Schwab125,9880 00For
QUANTITATIVE MASTER SERIES LLC70,8210 00For
Lincoln Financial37,6490 00For
Equitable36,8980 00For
Northern Trust32,8660 00For
AIG/SunAmerica22,2320 00For
Global X20,2970 00For
RBB FUND, INC.19,3880 00For
JPMorgan16,4140 00For
Brighthouse12,5340 3,0260For
Pacific Life14,6260 00For
Voya14,2880 00For
Dunham Funds12,6240 00For
Putnam00 12,3400Abstain
John Hancock11,4540 00For
MASTER INVESTMENT PORTFOLIO11,3100 00For
Goldman Sachs10,4470 00For
MFS8,7550 00For
Bridge Builder Trust8,3000 00For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

10. RATIFICATION OF THE SELECTION OF ROSE, SNYDER & JACOBS LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026

AUDIT-RELATEDMajority of the votes cast: yes

99% Majority: yes · of votes cast

FOR 99%
FOR: 43,057,620AGAINST: 562,751

Capricor Therapeutics, Inc.’s own tally for this item (“Proposal 2: The ratification of the appointment by the Audit Committee of the Company's Board of Directors of Rose, Snyder & Jacobs LLP as the Company's independent registered accounting firm for the fiscal year ending D”): 43,057,620 for, 562,751 against, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 57,664,673 outstanding shares: 75% for, 1.0% against (76% of the company cast a for/against vote).

The 47 asset managers below cast 99.9% of the shares they voted on this item FOR (6,284,723 for, 43 against).

FOR 99.9%
FOR: 6,284,723 (100.0%)AGAINST: 43 (0.0%)ABSTAIN: 3,026 (0.0%)
Largest asset managers voting on “RATIFICATION OF THE SELECTION OF ROSE, SNYDER & JACOBS LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIR” at Capricor Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,381,2881 00For
Fidelity1,143,1060 00For
State Street1,045,94042 00For
BlackRock785,5530 00For
TIAA212,7600 00For
Invesco154,1850 00For
Charles Schwab125,9880 00For
QUANTITATIVE MASTER SERIES LLC70,8210 00For
Lincoln Financial37,6490 00For
Equitable36,8980 00For
Northern Trust32,8660 00For
AIG/SunAmerica22,2320 00For
Global X20,2970 00For
RBB FUND, INC.19,3880 00For
JPMorgan16,4140 00For
Brighthouse12,5340 3,0260For
Pacific Life14,6260 00For
Voya14,2880 00For
Dunham Funds12,6240 00For
Putnam12,3400 00For
John Hancock11,4540 00For
MASTER INVESTMENT PORTFOLIO11,3100 00For
Goldman Sachs10,4470 00For
MFS8,7550 00For
Bridge Builder Trust8,3000 00For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

11. APPROVAL OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION REGARDING OFFICER EXCULPATION

CORPORATE GOVERNANCEMajority of the votes cast: yes

78% Majority: yes · of votes cast

FOR 78%AGAINST 22%
FOR: 23,472,207AGAINST: 6,433,198

Capricor Therapeutics, Inc.’s own tally for this item (“Proposal 5: To approve an amendment to the Certificate of Incorporation regarding officer exculpation.”): 23,472,207 for, 6,433,198 against, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 57,664,673 outstanding shares: 41% for, 11% against (51.9% of the company cast a for/against vote).

The 47 asset managers below cast 99% of the shares they voted on this item FOR (6,214,894 for, 69,869 against).

FOR 99%
FOR: 6,214,894 (98.8%)AGAINST: 69,869 (1.1%)ABSTAIN: 3,028 (0.0%)
Largest asset managers voting on “APPROVAL OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION REGARDING OFFICER EXCULPATION” at Capricor Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,379,7001,587 20For
Fidelity1,143,1060 00For
State Street1,045,648334 00For
BlackRock785,5530 00For
TIAA212,7600 00For
Invesco154,1850 00For
Charles Schwab125,9880 00For
QUANTITATIVE MASTER SERIES LLC70,8210 00For
Lincoln Financial26,20011,449 00For
Equitable36,8980 00For
Northern Trust32,8660 00For
AIG/SunAmerica22,2320 00For
Global X020,297 00Against
RBB FUND, INC.19,3880 00For
JPMorgan016,414 00Against
Brighthouse12,5340 3,0260For
Pacific Life14,6260 00For
Voya14,2880 00For
Dunham Funds12,6240 00For
Putnam12,3400 00For
John Hancock11,4540 00For
MASTER INVESTMENT PORTFOLIO11,3100 00For
Goldman Sachs10,4470 00For
MFS08,755 00Against
Bridge Builder Trust8,3000 00For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

12. ELECTION OF DIRECTORS: Linda Marban

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%WITHHELD 17%
FOR: 25,482,880WITHHELD: 5,310,512

Capricor Therapeutics, Inc.’s own tally for this item (“Elect Director: Linda Marbán, Ph.D.”): 25,482,880 for, 5,310,512 withheld, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 57,664,673 outstanding shares: 44% for, 9% withheld (53.4% of the company cast a for/withheld vote).

The 45 asset managers below cast 100% of the shares they voted on this item FOR (6,253,693 for, 0 against).

FOR 99.6%
FOR: 6,253,693 (99.7%)ABSTAIN: 20,116 (0.3%)
Largest asset managers voting on “ELECTION OF DIRECTORS: Linda Marban” at Capricor Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,377,9600 3,3290For
Fidelity1,143,1060 00For
State Street1,044,5620 1,4200For
BlackRock785,5530 00For
TIAA212,7600 00For
Invesco154,1850 00For
Charles Schwab125,9880 00For
QUANTITATIVE MASTER SERIES LLC70,8210 00For
Lincoln Financial37,6490 00For
Equitable36,8980 00For
Northern Trust32,8660 00For
AIG/SunAmerica22,2320 00For
Global X20,2970 00For
RBB FUND, INC.19,3880 00For
JPMorgan16,4140 00For
Brighthouse12,5340 3,0260For
Pacific Life14,6260 00For
Voya14,2880 00For
Putnam00 12,3400Abstain
John Hancock11,4540 00For
MASTER INVESTMENT PORTFOLIO11,3100 00For
Goldman Sachs10,4470 00For
MFS8,7550 00For
Bridge Builder Trust8,3000 00For
Prudential/PGIM7,2000 00For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

13. ELECTION OF DIRECTOR: Linda Marb?n

DIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (13,983 for, 0 against).

FOR: 13,983 (100.0%)
Largest asset managers voting on “ELECTION OF DIRECTOR: Linda Marb?n” at Capricor Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Dunham Funds12,6240 00For
NORTHERN LIGHTS FUND TRUST II1,3590 00For

14. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

— fund support · no official result

ONE YEAR 99.7%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

ONE YEAR: 2,900 (99.8%)NOT VOTED: 6 (0.2%)
Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at Capricor Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
APG Asset Management US Inc.00 00One Year
55I, LLC00 00Not Voted

Largest Capricor Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Capricor Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 57,664,673 shares outstanding at the time of that meeting.

Top Capricor Therapeutics, Inc. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 4.41%
2BlackRock 3.99%
3TANG CAPITAL MANAGEMENT LLC 3.72%
4State Street 3.29%
5MONTANOVA CAPITAL, LLC 3.05%
6Fidelity 2.79%
7RA CAPITAL MANAGEMENT, L.P. 2.61%
8Palo Alto Investors LP 2.22%
9GEODE CAPITAL MANAGEMENT, LLC 1.46%
10J. Goldman & Co LP 0.80%

Reported Capricor Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Capricor Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
Nippon Shinyaku Co., Ltd. 12.30% DEF14A
TANG CAPITAL MANAGEMENT, LLC 7.11% 13G
BlackRock 5.93% 13F
SUVRETTA CAPITAL MANAGEMENT, LLC 5.93% 13G
RA Capital Management, L.P. 5.23% 13G
Millennium Management LLC 5.10% 13G
Vanguard Group 4.44% 13F
State Street 3.78% 13F
Linda Marbán, Ph.D. 3.18% DEF14A
Citadel Advisors 2.50% 13F

Percentages above are of 57,664,673 shares outstanding, as reported by Capricor Therapeutics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Capricor Therapeutics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Capricor Therapeutics, Inc.'s shareholder meeting held 2026-06-04, in the 2025-2026 proxy season, 195 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,089 separate fund positions. Their filings are grouped here into 14 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — APPROVAL OF NAMED EXECUTIVE OFFICER COMPENSATION, ON A NON-BINDING ADVISORY BASIS — FOR was 80% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Capricor Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-08.

Capricor Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).